Home > Search Clinical Trials > All > Trial Details

Clinical Trial Details
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Clinical Trial ( IRB ) #: 15-115-1
Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Principal Investigator: Dr. Santhanan Lakshminarayanan
Description: The purpose of this study is to investigate the effectiveness and safety of riociguat (BAY 63-2521) in patients with diffuse cutaneous systemic sclerosis. It is approved by the FDA for the treatment of 2 forms of hypertension in lung blood vessels, chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat works by stimulating an enzyme in cells, which increases the production of another molecule. The resulting effects are a decrease in tissue fibrosis and relaxation of smooth muscle cells (cells found in particular internal organs and blood vessels). It is proposed that riociguat may offer protection against worsening diffuse cutaneous systemic sclerosis.
Classification:
  Rare Diseases
  Skin
Eligibility Criteria: Check with study contact
How to Contact: Kim Striegel. Telephone: 860-679-2589. Email: kstriegel@uchc.edu or Marie Breen. Telephone: Not available. Email: Not available